🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Transthyretin Cardiac Amyloidosis

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program NCT05040373n/a7 sites📍 Iowa City📍 Nantes📍 Münster Alnylam Pharmaceuticals Cardiac Magnetic Resonance and Echocardiography Study With Acoramidis NCT07695701Phase 41 site📍 St Louis Eidos Therapeutics, a BridgeBio company · Tests: Acoramidis (AG10) oral tablet Essen Amyloidosis Registry NCT06887283n/a1 site📍 Essen University Hospital, Essen A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting NCT07235462n/a17 sites📍 Multiple Locations📍 Multiple Locations📍 Multiple Locations Bayer · Tests: Acoramidis (356 mg film-coated tablets) Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy NCT06634108Phase 1, Phase 21 site📍 London London Health Sciences Centre Research Institute OR Lawson … · Tests: Genistein Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis NCT05758493Phase 21 site📍 Portland Oregon Health and Science University · Tests: 124I-Evuzamitide ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) NCT04561518n/a40 sites📍 La Jolla📍 Los Angeles📍 Jacksonville Alnylam Pharmaceuticals An Interventional Pilot Study to Investigate the Feasibility and Acceptance of a Structured Psychological Support Program for Patients, Caregivers, and Presymptomatic Carriers in Hereditary Transthyretin Amyloidosis With Cardiomyopathy NCT06907186NA1 site📍 Pavia Fondazione IRCCS Policlinico San Matteo di Pavia · Tests: Psychological Support Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis NCT06465810n/a89 sites📍 La Jolla📍 Los Angeles📍 San Francisco AstraZeneca · Tests: Treatment of transthyretin (ATTR) amyloidosis in observational study setting A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis. NCT07448623Phase 11 site📍 Groningen Novo Nordisk A/S · Tests: Coramitug Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations NCT07654855n/a6 sites📍 Los Angeles📍 Vancouver📍 Beijing AstraZeneca · Tests: None ( observational study ) A Phase 3 Study of NTLA-2001 in ATTRv-PN NCT06672237Phase 314 sites📍 Buenos Aires📍 Buenos Aires📍 San Juan Bautista Intellia Therapeutics · Tests: nexiguran ziclumeran, Normal Saline as Placebo Quantitative-imaging in Cardiac Transthyretin Amyloidosis NCT05776212n/a1 site📍 Groningen University of Edinburgh · Tests: 18F-fluoride PET Exploratory Study Evaluating the Relevance of [68Ga]Ga-FAPI-46 for Staging and Identifying Progressing Patients With Transthyretin Cardiac Amyloidosis NCT07549841Phase 21 site📍 Nantes Nantes University Hospital · Tests: [68Ga]Ga-FAPI-46 Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers NCT05489549n/a3 sites📍 New York📍 Cleveland📍 Dallas University of Texas Southwestern Medical Center Phenotypic Manifestations of Hereditary ATTR Amyloidosis NCT07124377n/a2 sites📍 Charata📍 Charata Hospital 9 de Julio de Las Breñas · Tests: A complete physical examination of all body systems, including height and body weight, Neurological examination include… US Benchmarking Clinical Study NCT07215715n/a3 sites📍 Boston📍 Boston📍 Boston eMyosound SAS The Italian Transthyretin Amyloidosis Web-Network NCT05444920n/a30 sites📍 Legnano📍 Orbassano📍 Ancona Fondazione IRCCS Policlinico San Matteo di Pavia Multimodality Cardiac Imaging for Disease Progression in ATTR-CM NCT07112066NA1 site📍 Zurich Dominik Benz · Tests: FAPI tracer Study of Acoramidis in Patients With Transthyretin Amyloid Cardiomyopathy NCT07791160n/a1 site📍 Many Locations Bayer · Tests: Acoramidis Comprehensive Program for Hereditary Transthyretin Amyloidosis NCT07213297n/a1 site📍 Canuelas Hospital de Alta Complejidad en Red · Tests: clinical assessments and complementary examinations TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy NCT07223203Phase 361 sites📍 Aurora📍 Chicago📍 Baltimore Alnylam Pharmaceuticals · Tests: Nucresiran, Vutrisiran Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause. NCT05950867NA1 site📍 Jette Universitair Ziekenhuis Brussel · Tests: ECG + echocardiography, Answering questionnaires Exercise Training in Transthyretin Cardiac Amyloidosis NCT05797857NA1 site📍 Boston Brigham and Women's Hospital · Tests: Exercise Training The Eplontersen Pregnancy and Lactation Outcomes Study NCT07205666n/a1 site📍 Frankfurt AstraZeneca NatiOnal Referral cenTEr Study of Transthyretin Amyloid Cardiomyopathy(ATTR) Patients on Tafamidis NCT06251778n/a1 site📍 Pavia Paolo Milani MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) NCT06128629Phase 3132 sites📍 Tucson📍 Los Angeles📍 Los Angeles Intellia Therapeutics · Tests: NTLA-2001, Placebo Quantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis NCT04535349NA2 sites📍 Caen📍 Lille University Hospital, Caen · Tests: Whole-body & CZT bone tracer imaging (SPECT) Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy NCT06082050EARLY Phase 11 site📍 Hangzhou Zhejiang University · Tests: YOLT-201 Thailand ATTR-CM Registry NCT06338696n/a8 sites📍 Bangkok📍 Bangkok📍 Bangkok Mahidol University · Tests: No intervention
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy